Sunitinib
Specifications
557795-19-4CAS Number
111-194-2EC Number
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamideIUPAC Name
C22H27FN4O2Chemical Formula
398.5 g/molMolecular Weight
Sunitinib; 557795-19-4; SU-11248; SU11248; sunitinibum; Su-011248; NSC-750690; N-[2-(diethylamino)ethyl]-5-{[(3Z)-5-fluoro-2-oxo-2,3-dihydro-1H-indol-3-ylidene]methyl}-2,4-dimethyl-1H-pyrrole-3-carboxamide; SU011248; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; NSC-736511; V99T50803M; n-(2-(diethylamino)ethyl)-5-((z)-(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl)-2,4-dimethyl-1h-pyrrole-3-carboxamide; DTXSID1041134; CHEBI:38940; 1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-(2-(DIETHYLAMINO)ETHYL)-5-((Z)-(5-FLUORO-2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXAMIDE; 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-; N-(2-(diethylamino)ethyl)-5-(((3Z)-5-fluoro-2-oxo-2,3-dihydro-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; RefChem:56080; DTXCID9021134; L01XE04; 111-194-2; 5-(5-fluoro-2-oxo-1,2-dihydroindolylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide; Sutent; Sunitinib Base; 342641-94-5; N-(2-(Diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; (Z)-N-(2-(Diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; MFCD09260778; Sunitinib (INN); Sunitinib [INN]; C22H27FN4O2; CHEMBL535; SU 11248; NSC750690; Sunitinib (free base); Sunitinib [INN:BAN]; NCGC00164631-01; Sunitinib base?; s7781; UNII-V99T50803M; HSDB 7932; (Z)-Sunitinib; 5-(5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide; 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide; Sutent (free base); Sunitinib (Standard); KS-5022; SUNITINIB [MI]; SUNITINIB [VANDF]; SCHEMBL8081; SUNITINIB [WHO-DD]; SUNITINIB [EMA EPAR]; BDBM4814; GTPL5713; orb1224671; orb1310675; orb3141251; Sutent, Sunitinib, SU11248; CHEBI:91430; EX-A553; WINHZLLDWRZWRT-ATVHPVEESA-N; HMS5085H20; HMS6018M17; HY-10255AR; K00588a; (E)-N-[2-(Diethylamono)ethyl]-5-[(5-fluoro-2-oxo-1,2-dihydro-3H-indole-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; Sunitinib base - Bio-X trade mark; EBC-12065; HY-10255A; NSC800937; T0374L; AKOS015908193; AKOS025312424; CCG-268638; CS-1670; DB01268; FD32120; NSC 736511; NSC 750690; NSC-800937; SDCCGSBI-0634415.P005; NCGC00164631-02; NCGC00164631-04; NCGC00164631-13; NCGC00164631-21; BD164426; N-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-2,3-dihydro-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-indolin-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; SY013948; NS00004661; D08552; EN300-323230; H38037; AB01273976-01; AB01273976-02; AB01273976_04; Q417542; SR-00000000005; SR-00000000005-2; BRD-K42828737-001-03-3; BRD-K42828737-044-09-0; BRD-K42828737-044-10-8; BRD-K42828737-044-12-4; Q27163278; Z2568722545; 1H-Pyrrole-3-carboxamide,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-; (Z)-N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-2-oxo-3-indolinylidene)methyl]-2,4-dimethylpyrrole-3-carboxamide; 5-[5-fluoro-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid(2-diethylamino-ethyl)-amide; N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1 pound not2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2 pound not4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboSynonyms
Products Containing Sunitinib
SUNITINIB VIATRIS 50 MG CAPSULAS DURAS EFGSUNITINIB VIATRIS 25 MG CAPSULAS DURAS EFGSUNITINIB VIATRIS 12,5 MG CAPSULAS DURAS EFGSUNITINIB TEVA 50 MG CAPSULAS DURAS EFGSUNITINIB TEVA 25 MG CAPSULAS DURAS EFGSUNITINIB TEVA 12,5 MG CAPSULAS DURAS EFGSUNITINIB ACCORD 50 mg CAPSULAS DURAS EFGSUNITINIB ACCORD 37,5 mg CAPSULAS DURAS EFGSUNITINIB ACCORD 25 mg CAPSULAS DURAS EFGSUNITINIB ACCORD 12,5 mg CAPSULAS DURAS EFGSUTENT 50 MG CAPSULAS DURASSUTENT 25 MG CAPSULAS DURAS
Page 1 of 5
Companies Selling Sunitinib
VS
VIATRIS SANTEFranceSA
SANDOZFranceAH
Accord Healthcare S.L.U.SpainVL
Viatris LimitedSpainPE
PFIZER EUROPE MA EEIGBelgiumPage 1 of 2